Tikcro Technologies (TIKRF) 0.6000 $TIKRF Tikcr
Post# of 273333
Posted On: 10/11/2015 6:54:14 AM
Tikcro Technologies (TIKRF) 0.6000 $TIKRF
Tikcro Technologies Reports Second Quarter 2015 Results
PR Newswire - Tue Jul 14, 10:31AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results for the second quarter ended June 30, 2015.
Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan
PR Newswire - Mon Jun 15, 7:30AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it will proceed with a pre-clinical plan for the generation and verification of new antibodies targeting the modulation of CTLA4 and PD1 cancer checkpoints.
Tikcro Technologies Reports First Quarter 2015 Results
PR Newswire - Wed May 27, 8:00AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results for the first quarter ended March 31, 2015.
Tikcro Technologies Announces Approval to Continue Trading on OTCQB
PR Newswire - Tue May 05, 8:42AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that the Company was approved to continue trading on OTCQB Marketplace, the market for developmental stage companies.
Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014
PR Newswire - Mon May 04, 7:45AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2014 with the U.S. Securities and Exchange Commission ("SEC"
. The annual report on Form 20-F contains information regarding its biotechnology project for the development of antibodies in the area of cancer immune checkpoints. This project aims to develop new antibodies with superior qualities of high specificity and binding in targeting certain identified immune checkpoints. The filing can be accessed on the SEC's website at http://www.sec.gov as well as via the Company's website at http://tikcro.com/annual-reports.
Tikcro Technologies Reports Fourth Quarter and Year End 2014 Results
PR Newswire - Tue Mar 10, 7:30AM CDT
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the fourth quarter and the year ended December 31, 2014.
Tikcro Technologies Announces Shareholders' Meeting
PR Newswire - Wed Feb 18, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that an Extraordinary General Meeting of Shareholders will be held on March 25, 2015 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.
Tikcro Signs Research and License Agreement Regarding Cancer Immune Checkpoint Antibodies
PR Newswire - Tue Dec 30, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel. This agreement is for the development of new antibodies originating from specified research at the Weizmann Institute of Science addressing identified targets of cancer immune checkpoints.
Tikcro Technologies Announces 2014 Annual General Meeting
PR Newswire - Mon Nov 24, 8:20AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on December 29, 2014 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.
Tikcro Technologies Reports Third Quarter 2014 Results
PR Newswire - Thu Nov 13, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the third quarter ended September 30, 2014.
Tikcro Technologies Reports Second Quarter 2015 Results
PR Newswire - Tue Jul 14, 10:31AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results for the second quarter ended June 30, 2015.
Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan
PR Newswire - Mon Jun 15, 7:30AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it will proceed with a pre-clinical plan for the generation and verification of new antibodies targeting the modulation of CTLA4 and PD1 cancer checkpoints.
Tikcro Technologies Reports First Quarter 2015 Results
PR Newswire - Wed May 27, 8:00AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results for the first quarter ended March 31, 2015.
Tikcro Technologies Announces Approval to Continue Trading on OTCQB
PR Newswire - Tue May 05, 8:42AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that the Company was approved to continue trading on OTCQB Marketplace, the market for developmental stage companies.
Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014
PR Newswire - Mon May 04, 7:45AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2014 with the U.S. Securities and Exchange Commission ("SEC"
. The annual report on Form 20-F contains information regarding its biotechnology project for the development of antibodies in the area of cancer immune checkpoints. This project aims to develop new antibodies with superior qualities of high specificity and binding in targeting certain identified immune checkpoints. The filing can be accessed on the SEC's website at http://www.sec.gov as well as via the Company's website at http://tikcro.com/annual-reports. Tikcro Technologies Reports Fourth Quarter and Year End 2014 Results
PR Newswire - Tue Mar 10, 7:30AM CDT
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the fourth quarter and the year ended December 31, 2014.
Tikcro Technologies Announces Shareholders' Meeting
PR Newswire - Wed Feb 18, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that an Extraordinary General Meeting of Shareholders will be held on March 25, 2015 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.
Tikcro Signs Research and License Agreement Regarding Cancer Immune Checkpoint Antibodies
PR Newswire - Tue Dec 30, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel. This agreement is for the development of new antibodies originating from specified research at the Weizmann Institute of Science addressing identified targets of cancer immune checkpoints.
Tikcro Technologies Announces 2014 Annual General Meeting
PR Newswire - Mon Nov 24, 8:20AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on December 29, 2014 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.
Tikcro Technologies Reports Third Quarter 2014 Results
PR Newswire - Thu Nov 13, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the third quarter ended September 30, 2014.
(0)
(0)